此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

卡维地洛对接受蒽环类药物治疗的癌症患者心脏毒性的影响 (CardioTox)

2026年9月29日 更新者:Hospital Sirio-Libanes

一项评估卡维地洛对接受蒽环类药物治疗的癌症患者心脏毒性影响的前瞻性多中心随机研究

Neoplasia is the main cause of general death in the Brazilian population. In 2016, they were responsible for approximately 211,343 (16%) deaths, followed by cardiovascular diseases (12.6%). Despite the high mortality rate of neoplasia, oncological treatment have advanced substantially in recent decades improving the prognosis of patients. However, growing evidence suggest that some oncological agents may induce significant toxicity that may play a major role in the quality of life, morbidity and mortality. The cardiovascular system is often negatively affected with cancer therapy, predisposing several patients to stop appropriate treatments or to have cardiovascular events related to the cardiotoxicity. The most typical manifestation of cardiotoxicity and related consequences (heart failure) are related to the use of anthracyclines. Anthracyclines are part of the chemotherapy regimen for solid tumors and hematological neoplasms in children and adults, and are associated with an increase in life expectancy. Carvedilol is an α and β-blocker that also has antioxidant properties. Preliminary studies have shown that carvedilol and its metabolites prevent lipid peroxidation, inhibit the formation and inactivate free radicals, in addition to preventing the depletion of endogenous antioxidants, such as vitamin E. These effects would potentially prevent anthracycline injury but definitive evidence is still needed. This is a multi-center, double-blind, randomized, placebo-controlled study that aims to establish the efficacy of carvedilol for the primary prevention of left ventricular systolic dysfunction in cancer patients obtained with anthracycline chemotherapy, in different schedules and doses.

研究概览

地位

主动,不招人

条件

研究类型

介入性

注册 (估计的)

1018

阶段

  • 第四阶段

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

    • São Paulo
      • São Paulo、São Paulo、巴西、01308-050
        • Hospital Sirio Libanes

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 及以上 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

  • ≥18 years of age at the time of screening
  • Cancer patients that will receive chemotherapy with anthracyclines.

Exclusion Criteria:

  • Inability to adequate asses left ventricular function
  • Previous symptoms (dyspnea on exertion, orthopnea, paroxysmal nocturnal dyspnea, and pulmonary and systemic congestion) suggestive of or a previous diagnosis of heart failure.
  • Previous history of any cardiomyopathy (eg.: valve disease, Chagas' disease, infiltrative cardiomyopathy)
  • LVEF < 50%
  • Previous history of myocardial revascularization
  • Permanent tachyarrhythmia (flutter, atrial fibrillation, atrial tachycardia)
  • Congenital heart disease with left ventricular function impared
  • Contra-indication to the use of beta-blockers.
  • Pregnant or Breast-feeding females or women of childbearing age who intend to became pregnant.
  • On kidney replacement therapy
  • ECOG >= 4 or Karnofsky <=30
  • Advanced hepatic failure (C score Child-Pugh and MELD > 15);
  • Previous use of anthracycline
  • Have any serious concomitant systemic disease, condition, or disorder that, in the opinion of the investigator, should preclude participation in this study
  • Are concurrently enrolled in any other type of medical research judged not to be scientifically or medically compatible with this study

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:预防
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:双倍的

武器和干预

参与者组/臂
干预/治疗
实验性的:Intervention Group

Patients allocated to the intervention group will receive carvedilol 6.25 mg twice daily, then increased to 12.5 mg twice daily, until maximum dose of 25 mg twice daily according to the patients' tolerance; The dosis increments will occur every 5 days. If after the increment the patient develops bradycardia or hypotension, the dose will be reduced to the maximum tolerated dose. Carvedilol will ideally be maintained for up to 30 days after the end of chemotherapy.

Carvedilol will be dispensed in a staggered and progressive manner, initially from 6.25 mg twice daily, then increased to 12.5 mg twice daily, until maximum dose of 25 mg twice daily or development of contraindications

安慰剂比较:Control Group

Patients allocated to this group will receive placebo in a presumably staggered and progressive manner similar to the group intervention. The placebo will ideally be maintained for up to 30 days after the end of chemotherapy.

Patients will receive placebo in a presumed staggered and progressive manner similar to the intervention group. The placebo will ideally be maintained for up to 30 days after the end of chemotherapy.

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Drop in ejection fraction within 12 months of starting treatment.
大体时间:12 months

Drop in ejection fraction> 10% to values less than 50% of the left ventricle

12 months
Cardiac events within 12 months of starting treatment.
大体时间:12 months

Cardiac events such as death, resuscitated cardiac arrest, myocardial infarction, heart failure and cardiac arrhythmias

12 months

次要结果测量

结果测量
措施说明
大体时间
Drop in ejection fraction within 12 months.
大体时间:12 months

Drop in ejection fraction greater than 10% and values less than 55%

12 months
Reduction in myocardial strain in 12 months from the start of treatment.
大体时间:12 months

Relative reduction of more than 15% in myocardial strain

12 months
Diastolic dysfunction within 12 months
大体时间:12 months

Development of diastolic dysfunction within 12 months

12 months
Elevation of biomarkers during chemotherapy and up to 12 months of follow-up
大体时间:12 months

Elevation of biomarkers (NT-pro BNP and troponin) during chemotherapy and up to 24 months of follow-up

12 months
Quality of life (EuroQol-5D).
大体时间:12 months

Quality of life measured by questionnaire in up to 12 months.

12 months
Cardiovascular complications in 12 months.
大体时间:12 months

Cardiovascular complications (death, resuscitated cardiac arrest, myocardial infarction, heart failure and cardiac arrhythmias) in 24 months.

12 months

其他结果措施

结果测量
措施说明
大体时间
Diagnosis of neoplasia within 12 months.
大体时间:12 months

Diagnosis of another neoplasia

12 months
Progression of oncological disease within 12 months.
大体时间:12 months

Progression of oncological disease

12 months
Tumor recurrence within 12 months.
大体时间:12 months.

Tumor recurrence

12 months.

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 首席研究员:Renato H D. lopes, MD, PhD、Hospital Sirio-Libanes

出版物和有用的链接

负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2021年8月1日

初级完成 (估计的)

2027年5月31日

研究完成 (估计的)

2027年5月31日

研究注册日期

首次提交

2021年6月17日

首先提交符合 QC 标准的

2021年6月17日

首次发布 (实际的)

2021年6月25日

研究记录更新

最后更新发布 (实际的)

2026年10月2日

上次提交的符合 QC 标准的更新

2026年9月29日

最后验证

2026年8月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

不

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

在美国制造并从美国出口的产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅